

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Artificial intelligence-based skin diseases detection medical device.

Aditi Kamanna Pujari ¹, Dnyaneshwari Pawar², Prof. Sushma Nakhate ³, Dr. Tushar. T. Shelke⁴

¹ Address:-Genba Sopanrao Moze College Of Pharmacy, Wagholi,pune

Email ID:- pujariaditi02@gmail.co,

² Adress:- Genba Sopanrao Moze College Of Pharmacy, Wagholi, Pune

Email ID:- dnyaneshwaripawar41@gmail.com

³ Adress:- Genba Sopanrao Moze College Of Pharmacy, Wagholi, Pune

Email ID:- sushmanakhate2017@gmail.com

⁴ Adress:- Genba Sopanrao Moze College Of Pharmacy, Wagholi, Pune

ABSTRACT:

From common conditions such as psoriasis, eczema, and acne to debilitating malignancies such as melanoma, skin disorders affect people worldwide. Rapid, precise, and moderately affordable detection methods are necessary owing to the increased incidence of skin malignancies. Although effective, existing technologies—clinical visualization, dermoscopy, and biopsy—are limited by inter-observer variability, subjectivity, invasiveness, and accessibility. The practice of dermatology has been revolutionized with the help of artificial intelligence (AI), and specifically with deep learning. High-volume dermoscopic image datasets such as PH2, HAM10000, and ISIC facilitate easier training and validation of models of AI; however, this is with the significant penalty of dataset skewing toward lighter skins. Accuracy, sensitivity, specificity, F1-score, AUC-ROC, and segmentation parameters such as Dice and Jaccard are utilized to assess AI.

AI proves as good as or better than doctors in controlled settings, best exemplified by melanoma detection, but actual performance needs to be carefully tracked. Explainable AI (XAI) methods like saliency maps and Grad-CAM enhance interpretability and trust with clinicians. AI incorporation is enhancing dermatologic practice with teledermatology, handheld dermatoscopes, and AI-assisted triage, while multimodal systems that integrate images, clinical metadata, and patient genetics are propelling precision dermatology.

AI performs as well as or even better than dermatologists in ideal circumstances, including notably melanoma identification, but its performance in actual use must be strictly watched. Explainable artificial intelligence (XAI) methods like saliency maps and Grad-CAM enhance interpretability and clinician confidence. AI incorporation is enhancing dermatologic practice by way of teledermatology, hand-held dermatoscopes, and AI-based triage, while multimodal systems that integrate images, clinical metadata, and patient genetics are advancing precision dermatology.

Introduction

Skin diseases are among the most prevalent human clinical conditions in the world, occurring in individuals of any age, race, and geographic origin. They range from pervasive ailments such as psoriasis, eczema, and acne to potentially fatal cancers like melanoma, basal cell carcinoma, and squamous cell carcinoma. Traditional diagnostic techniques—such as direct visual examination, dermoscopy, and biopsy—have long been the standard in dermatology, but are bound by aspects of subjectivity, intrusiveness, time requirements, availability, andinter-observer variation.

Artificial intelligence (AI) and deep learning methods like Convolutional Neural Networks (CNNs), Vision Transformers, and ensemble models, has been a revolutionary technology for dermatological diagnosis. Such models are able to successfully diagnose intricate skin lesion images and differentiate benign from malignant conditions. Publicly available data, such as PH2, HAM10000, and the ISIC archive, have sped up AI model training and testing, with work still to be done in dataset variety and bias, especially for skin tone, lesion morphology, and demographics. Explainable AI (XAI) methods—e.g., saliency maps, Grad-CAM visualizations, and attention mechanisms—improve interpretability, establish clinical trust, and enable regulatory compliance.

Teledermatology systems, hand-held dermatoscopes based on AI, and mobile app technology extend diagnostic capabilities to underserved areas. Research has shown that AI systems can match diagnostic accuracy of expert dermatologists, especially for melanoma, and that AI may augment, not displace, human expertise. New methods like multimodal learning, where images are integrated with clinical and demographic information, and federated learning, that maintains the privacy of patients but allows multi-institutional cooperation, are further evolving individualized and secure dermatological treatment.

Athough it has its revolutionary promise, AI in dermatology presents ethical, regulatory, and pragmatic challenges. Algorithmic transparency, equal access, confidentiality of patient data, and compliance with regulatory expectations are among the issues to be solved to enable safe and effective use. In general, AI-augmented skin disease diagnosis has the potential to revolutionize dermatology through enhanced diagnostic accuracy, faster earlier detection, increased access to care, and augmentation of clinician expertise. [10]

Rationale / Novelty

Artificial intelligence (AI) is proving to be a disruptive agency in medical diagnostics, especially in dermatology, whereby it compensates for the limitations of conventional methods. Standard methods of diagnostics like visual inspection, dermatoscopic images, and histopathology are efficient but limited by human biases such as inter-observer difference, subjectivity in interpretation, and fatigue. They result in varied outputs, slow identification of skin malignancies, and inferior planning of treatments. AI-based diagnostic systems, on the other hand, can work through large data pools, pick up minute and minute details beyond human capacity to discern, and give consistent and reproducible results across clinical platforms.[1,5]

One of AI strengths in dermatology is its accuracy in diagnosis. Convolution Neural Networks (CNNs) have repeatedly reached dermatologists' performance in classifying skin lesions and even exceeded that of human specialists. For example, Esteva et al. (2017) recently proved that CNN-based systems could differentiate malignant from benign tumors from dermoscopic images with high accuracy. Along similar lines, [1, 26] proved that AI exceeded dermatologists' performance when classifying melanomas. Beyond melanomas, AI has also indicated strong potential when detecting squamous cell carcinoma as well as basal cell carcinoma and benign lesions, indicating its performance in a wide range of clinical situations [23,7]

Of equal significance is scalability and access that AI provides to dermatological practice. Conventional diagnoses usually necessitate face-to-face consultation to expert clinics that may present difficulties in underserved areas. AI-based tools that include phone applications and handheld dermatoscopes enable dermatological examination to happen from a distance significantly enhancing access. Novel techniques such as federated learning improve scalability further by permitting institution-Level co-training of models without loss of confidentiality of patients so enhancing generalizability without loss of representation of varied types of skin, morphology of lesions as well as of demographic sections [45,46].

Another important strength of AI is clinical integration. As decision support systems, AI systems aid dermatologists in short-listing high-risk lesions, triaging patients expeditiously, and providing evidence-based plan-assistance in treatments. Triage systems automated can quickly flag suspect lesions among large patient pools so that high-risk cases can receive timely focus. By integrating further into electronic health records (EHRs) as well, longitudinal follow-up of skin disorders is possible to facilitate personalized plantracking of treatments. [47,49]

New breakthroughs push AI usage far beyond image classification. Configuration such as multispectral dermoscopy, three-dimensional images, and multimodal learning—to which dermoscopic images are incorporated along with clinical metadata, demographics, and medical history—confer higher diagnostic information. Of particular interest is that multimodal systems have been proven to surpass a single-modality system, providing customized risk prediction and more specific therapies. [41]

AI is also pivotal in prevention and early detection. Early melanomas, as a class of tumors, present minor morphological variations that are frequently overlooked during daily clinical examination. AI programs trained on large annotated databases are capable of detecting such variations with high sensitizeability so that earlier intervention occurs and morbidity and mortality are significantly minimized. Additionally, AI-based monitoring systems allow real-time monitoring of high-risk patients through suspect identification of long-term morphological variations of signs, changing dermatology from a reactive to a proactive speciality. [43,41]

Deep learning interpretability challenge is being solved by Explainable AI (XAI). Algorithms like saliency maps, Grad-CAM images, and attention networks illuminate most responsible image parts of AI prediction. This interpretability boosts doctor trust, enables ethical deployment, and allows regulatory clearance. [28]; [29] Moreover, AI helps in dermatological studies and epoch hygiene through detection of hitherto underrepresented types of lesisons, detection of gaps in datasets, and facilitation of large studies of epidemic scale. These functions do not only speed up creation of more generalizable models but also enhance health policy as well as planning.[17,11] Finally, AI's distinctiveness in dermatology is its capacity to provide higher diagnostic accuracy, expand access through scale-able instruments, integrate into practice clinical practice, improve preventive medicine, and offer explainable, evidence-based results.




Fig 1. [71]

Objectives

This review's overarching goal is to conduct a comprehensive examination of where artificial intelligence (AI) stands in terms of dermatology, including medical devices that can be used to detect skin ailments.

1. Critique AI Methodologies

This review's principal aim is to review the diversity of AI methods employed in skin disease identification. By automatically learning medical images' hierarchical information, the potential of Convolutional Neural Networks (CNNs) to make them a highly-used approach is a significant part of this recognition. Esteva et al. (2017) pointed out CNNs' effectiveness in clinical practice when they demonstrated that CNNs could classificatorylangleinceratbermanial and malignant lesions to a dermatologists' standard. Beyond CNNs, an emerging Vision Transformers (ViTs) approach is promising higher performance in difficult classification tasks and long-range dependencies identification in image data. [40,37] Ensemble learning methods that combine multiple AI models to offset individual failures have been proven to raise robustness and generalisability on a myriad of datasets. [7,32] By comparing their architectural patterns, training methods, and appropriateness to diverse skin photo-lesions—even from benign nevi through to melanoma—this review attempts to systematically survey these methods. To understand how advances in method would enhance diagnostic accuracy and clinical utility, systems that are a combination of CNNs and traditional image-processing methods or exploit multimodal information are further explored. [21,41]

2. Track Performance Metrics

Comprehensive examination of indicated performance measures of AI-based skin disease detection studies is the second objective. Convenient information regarding how well and reliably a model performs is offered by measures such as diagnostic accuracy, sensitivity, specificity, precision, recall, and Area Under the Receiver Operating Characteristic Curve (AUCROC). Several studies have indicated that AI models can match or surpass experienced dermatologists' performance. [17,24] Yet, performance varies substantially across datasets, skin types, and types of lesions, thus the model's generalisability must be evaluated vigilantly. To ensure published measures adequately represent clinical utility, this objective also involves a rigorous investigation of benchmarking processes, dataset reliability, and assessment methods. [2,16]

3. Recognize Problems

Even if AI holds much promise in dermatology, a series of challenges hinder its wide application. This review's main aim is to find and scrutinize such challenges. As most of the models have been trained mainly on lighter skin types or specific types of lesions, dataset bias and lack of cultural diversity are grave issues as they hinder the models from being transferred to a range of patient populations. [36,31] Interpretability is another important challenge. Even if deep learning models are so highly accurate, they many a time work as "black boxes" that make it hard to understand from a physician's perspective whatever assumptions underlie the model's prediction. To address this challenge, explainable AI (XAI) techniques such as saliency maps and Grad-CAM have been proposed. Selvaraju et al. (2017) and Ribeiro et al. (2016). Another challenge is that of regulatory compliance, as to make sure that AI-based medical devices are safe and work effectively, they ought to abide by rigorous guidelines set by organizations such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration [FDA]. [26,27] Implementation is made harder by ethical considerations such as protection of data, informed permission, as well as equal access even if especially in global clinical environments that have varying laws. [43] This document tries to provide real-world insights into developing more reliable, transparent, as well as morally good AI systems by systematically tackling these challenges.

4. Experience Clinical Integration

Analyzing AI system incorporation into clinical workflows and assessing their impact on healthcare providing is another important objective. By automatically repeating tasks, signaling high-risk cases to specialists, and providing decision support, AI-based dermatology systems are capable of aiding physicians. For instance, teledermatology platforms and mobile apps allow remote skin lesion screening to improve access to care in underserved regions. [25, 46] By flagging patients requiring urgent attention and reducing diagnostic delays, AI-assisted triage systems have the potential to make workflows more efficient. [49] Alongside determining clinician acceptance, integration with electronic health records, and potential human-AI collaborative decision-making, the assessment also investigates AI application in hospital and clinic environments. [24,17]

5. Propose Future Directions

Final aim of this review is to propose potential directions of inquiry and development of Albased dermatology. To reduce bias and to improve model generalisability, development of more representative and diverse datasets is one of the most critical areas. [2,36] To increase model transparency, to build clinician trust, and to ease regulatory approval, explainable AI needs to move forward. [28,29] To provide more complete and personalized diagnostics, developing reliable validation processes, longitudinal monitoring systems, and multimodal AI models that combine dermoscopic, clinical, and patient metadata is what research should also focus on. [12,11]



Fig 2.

Literature Survey

In dermatology practice, artificial intelligence (AI) is a revolutionary technology, and an increasing number of studies are examining its potential application to skin disease detection.

Models of AI Artificial

Deep learning methods are utilised in most dermatology research, with Convolutional Neural Networks (CNNs) being the most popular architecture. CNNs are especially good at automatically classifying skin lesions by extracting hierarchical features from dermatological photos. Because of their excellent accuracy, computational efficiency, and capacity to generalise across a variety of datasets, architectures like Res Net [38] and EfficientNet [39] have been widely used. ResNet is appropriate for challenging image classification applications because it uses residual connections, which enable very deep networks without sacrificing performance. [38] In contrast, EfficientNet achieves state-of-the-art performance at a lower computational cost by optimising network depth, width, and resolution through the use of compound model scaling. [39] In addition to CNNs, Vision Transformers (ViTs) have been investigated recently for the classification of skin lesions. ViTs perform better in detecting minute details within lesions by using self-attention mechanisms to collect long-range relationships in picture data. [40,37] To increase resilience and lessen vulnerability to individual model biases, ensemble learning techniques—which integrate predictions from several AI models—have also been studied. [7,32] Additionally, hybrid models that combine deep learning with traditional image processing methods have shown enhanced accuracy in feature extraction and classification, especially in difficult situations with uneven lesion boundaries or poor contrast. [3]

Data Collection

High-quality large data sets have been central to AI application work in dermatology. Data sets that can be publicly released such as HAM10000 and the International Skin Imaging

Collaboration (ISIC) collection have thousands of dermoscopically marked images of a diverse set of skin lesions that range from melanoma to basal cell carcinoma to squamous cell carcinoma to benign nevi. [2,1] These data sets make studies comparable by enabling researchers to train and test AI systems against a diverse set of images. Smaller but high-resolution images that are densely annotated are offered by the PH2 data set and can be used to challenge classification as well as segmentation models. [4]

Diverse datasets are necessary to foster model generalisability, according to most recent studies. Questions have been raised about the diagnostic accuracy of varying ethnic groups given that most AI models have been trained predominantly on lighter pigment. [39] To reduce bias and foster equal performance among a diverse population of patients, efforts have been made to expand representation of datasets and add images from varied groups. To enable training across institutions without compromising patient confidentiality, techniques of federated learning have also been tried. This allows AI systems to access a higher diversity of information without centralising sensitive information. [45,46]

Metrics of Assessment

In order to be clinically useful, AI models have to be properly assessed. Precision, recall, Area Under the Receiver Operating Characteristic Curve (AUC-ROC), accuracy, sensitivity, and specificity are most commonly reported measures. While sensitivity and specificity provide an estimate of model ability to appropriately predict positive and negative examples, respectively, accuracy provides an estimate of proportion of appropriate prediction. AUC-ROC provides a general estimate of model discrimination on a continuum of thresholds. With these measures, studies have repeatedly validated that AI models work well, often equivalent to or better than that of dermatologists' discriminative capacity in specific tasks, such as melanoma detection. [17,24]

However, benchmarking methods vary in studies due to variations of assessment routines, preprocessing methods, and data partitions. Standardized assessment pipelines—to which those suggested by ISIC challenges belong [3,9]—should be assured to make studies comparable and consistent.

Aim of AI In Dermatology

Usage of AI is limited in a broad area of dermatology by a continuum of challenges in spite of such progresses documented in literature. Dataset bias is one of the lead challenges.

Generalisation of a model to underrepresented populations is limited by that most of datasets are biased towards lighter skin tones, particular types of lesions, or particular age groups. [36,31] Standardised imaging methods are needed as model performance is further influenced by heterogeneity of imaging conditions such as lighting, resolution, and device type.

Another critical problem is interpretability. Deep learning models are often "black boxes" such that it is difficult for medical professionals to understand rationale behind predictions. Saliency maps and Grad-CAM have been suggested as explainable AI (XAI) methods that have been put forward as a solution to this challenge by visually determining parts of an image that influence model decisions. [28,29] More work is needed to standardize interpretability methods and implement them effectively in clinical workflows.

Regulatory challenges pose an additional challenge. Software as a Medical Device (SaMD) is the term used to refer to AI-enabled dermatology devices that come under rigorous control of such authorities as the FDA and EMA. [26,27] Clearance by a regulator necessitates a demonstration of effectiveness and safety as well as predictable functioning in real-life settings. Advances are also hindered by ethical considerations such as confidentiality of patients, informed consent, and equal access all the more so in resource-starved environments.

Latest Developments and Trends

Quite a number of innovative developments in AI dermatology have been incorporated in recent articles. Multimodal learning has been revealed to have potential in enhancing diagnostic performance and personalized risk forecasting through integration of dermoscopic images with clinical metadata like age, gender, site of lesion, and medical background. [41] Methods of federated learning promote diversity and confidentiality by enabling cooperative model learning among institutions without centralising sensitive patient information. Furthermore, innovative new imaging modalities like multispectral imaging, three-dimensional dermoscopy, and highdefinition smartphone-based dermatoscopes are enhancing remote diagnoses and expanding AI systems' capabilities. [25,46]

Methods and Materials

There is a requirement for an interdisciplinary blend of dermatology, computer science, data science, regulatory science, and clinical verification for the development and evaluation of artificial intelligence (AI)-based medical devices for the diagnosis of skin diseases.

1. Sources of Information and Imaging Modalities

High-quality annotated dataset is needed to train AI models for the diagnosis and classification of skin lesions. Research has been significantly facilitated by publicly available repositories:

- Seven diagnostic classes contain over 10,000 dermoscopic images in the HAM10000 dataset. [2]
- The ISIC Archive and Challenges, which set the benchmark for classification, segmentation, and detection tasks each year, have become the gold standard. [21,20]
- There are 200 dermoscopic images with expert comments available in the PH2 database.

[4]

Use of dermoscopy, confocal microscopy scans, clinical photos, and smartphone images is increasing .[25,11]

2. Image augmentation and preprocessing

Artefacts such as hair, shine, or changing lighting are found regularly in unprocessed dermatological images. Han et al. (2018) claim that preprocessing operations often entail:

- Colour normalisation to normalise across devices.
- Removal of hair algorithms employing inpainting approaches or DullRazor. [22]
- Spatial sharpening of lesion borders and contrast enhancement to make segmentation easier. [13]

Augmentation methods such as flipping, rotation, zooming, Gaussian noise addition, and synthetic data generation using GANs have also been employed to counter dataset imbalance and small sample sizes. [48]

3. Model Structures

The most prevalent methodological paradigm today is deep learning: Convolutional Neural Networks (CNNs): In lesion classification, architectures such as VGGNet, ResNet [38], and EfficientNet [39] are used commonly.

- Segment models are used in feature extraction; U-Net [8] and two-stage frameworks [14] segment lesion boundaries.
- Hybrid and ensemble models: Using deep and manually designed features or stacking multiple CNNs makes them more robust [34,32]
- ViTs, or vision transformers: Since they are capable of emulating long-range dependencies, newer attempts [40,37] work better on dermoscopic data.

To address the absence of dermatology-specific data, transfer learning and fine-tuning of huge picture datasets (such as ImageNet) remain a necessity.

[33]

4. Training and Optimising Models

Deep networks are trained on the following loss functions for dermatological applications: • Dice/Jaccard loss for segmentation, and cross-entropy for classification.

- Adam or SGD optimisers with cycle learning rates are some examples of optimisation methods. [6]
- Regularisation: Early stopping, dropout layers, and batch normalisation prevent overfitting.
- Hyperparameter tuning: Grid search and Bayesian optimisation are frequently cited. [15]

To enable multi-center collaboration with no data sharing, privacy-preserving approaches such as federated learning have been explored. [45]

5. Evaluation Measures

Both technical performance measures and clinical relevance measures are required for effective evaluation:4

- Segmentation tasks include border error, Jaccard index, and dice similarity coefficient.
- Calibration: Measures such as Expected Calibration Error (ECE) are used to guarantee dependability. [30]
- Explainability: Grad-CAM [29] and other visualisation techniques improve interpretability for medical professionals.

Research shows that AI performance is either equal to or better than dermatologists in terms of diagnostic accuracy. [1, 5,]

6. Regulatory Considerations and Clinical Validation

Rigorous validation is called for to bridge the gap between clinic and lab:

- Reader studies: Comparison of expert dermatalogists with AI predictions.[24,19]
- Real-time operation in outpatient dermatology clinics is one of the potential experiments. [18]
- Mobile app assessments: Accuracy and usability testing in apps that patients engage with.

[11]

For AI-enabled Software as a Medical Device (SaMD), authorities such as the FDA, EMA, and

MHRA emphasize strongly post-market surveillance, generalisability, and transparency. [26,27] Reporting follows standards such as TRIPOD-AI and CONSORT-AI.[47]

7. Deployment Environments

The infrastructure used consists of deployment equipment alongside datasets and models:

"integration: Edge-optimized, lightweight CNNs for patient triage.[46]

- Cloud computing solutions: Enables dermatologists to remotely access AI models, enabling teledermatology.
- Workflow integration: Integration of AI technologies into teleconsultation platforms and Electronic Health Records (EHRs). [49]

Ongoing monitoring frameworks provision [50], dealing with a range of skin colors [36], and ensuring adversarial robustness [35] are some of the challenges.

8. Multimodal and future-oriented solutions

To enhance diagnostic accuracy, recent advancements focus heavily on combining multimodal data, integrating genetic, clinical, and dermoscopic data. [51]

Acknowledgement

The author wishes to express sincere gratitude to Prof. Sushma Nakhate for her invaluable guidance, insightful suggestions, and continuous encouragement throughout the preparation of this review. Her mentorship not only shaped the scientific direction of this work but also provided clarity and motivation at every stage of its development.

The author also extends heartfelt thanks to the faculty and staff of Genba Sopanrao Moze College of Pharmacy, whose constant support, access to academic resources, and nurturing research environment were instrumental in completing this manuscript. Their commitment to fostering a culture of academic excellence and collaborative learning greatly enriched the quality of this work.

Finally, the author acknowledges the broader academic community and peers whose discussions, feedback, and exchange of ideas have contributed, both directly and indirectly, to the refinement of this review.

Conclusion

Deep learning, as artificial intelligence (AI), progressed rapidly from theory to clinical practice in dermatology and equaled or surpassed that of expert dermatologists in diagnostic capability. Huge data sets and large studies—PH2, HAM10000, and ISIC—have enabled the creation of strong and unbiased models. Techniques such as CNNs, vision transformers, ResNet, EfficientNet, U-Net, ensemble modeling, transfer learning, and data augmentation have improved image classification and segmentation.

Besides accuracy, explainability, security, and real-world usability, the following are key: AI integrated in teledermatology, mobile dermatoscopes, and apps while ensuring compliance with regulation guidelines like FDA, TRIPOD-AI, and CONSORT-AI. Challenges remain, including bias reduction, treatment of heterogeneous data, and trouble-free clinical workflow integration.

Future horizons involve multimodal data fusion to better enable personalized diagnosis, rendering AI an invaluable companion that enhances clinicians' knowledge and augments patient care in dermatology.

REFERENCES:-

- Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115-118.
- Tschandl P, Rosendahl C, Kittler H. The HAM10000 dataset, a large collection of multi-source dermatoscopic images of common pigmented skin lesions. Scientific Data. 2018;5:180161.
- Codella N, Rotemberg V, Tschandl P, et al. Skin Lesion Analysis Toward Melanoma Detection 2018: A Challenge Hosted by the International Skin Imaging Collaboration (ISIC). arXiv:1902.03368; 2019.
- 4. Mendonça T, Ferreira PM, Marques JS, Marcal ARS, Rozeira J. PH2 a dermoscopic image database for research and benchmarking. 2013.
- Brinker TJ, Hekler A, Enk AH, et al. Deep neural networks are superior to dermatologists in melanoma image classification. European Journal of Cancer. 2019.
- 6. Ray A, Sinha S, Chakraborty C. Skin Lesion Classification With Deep Convolutional Neural Networks. JMIR Dermatology. 2020.
- 7. Milton MA. Automated Skin Lesion Classification Using Ensemble of Deep Neural Networks in ISIC 2018. arXiv:1901.10802; 2019.
- 8. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image Segmentation. MICCAI. 2015.
- 9. Cassidy B. Analysis of the ISIC image datasets: Usage, benchmarks and lessons learned. 2022.
- 10. Jeong HK, Park JH, Yoon JD, et al. Deep Learning in Dermatology: A Systematic Review. 2022.
- 11. Wongvibulsin S, et al. Current State of Dermatology Mobile Applications With AI Features. 2024.
- 12. Cai ZR, et al. Assessing the performance of AI models in dermatology. 2025.
- 13. Hwang YN, et al. Segmentation of Melanocytic Skin Lesions. 2021.
- 14. Manzoor K, et al. Dual-stage segmentation and classification framework for skin lesion analysis. 2025.
- 15. Selvaraj KM, et al. Enhancing skin lesion classification with advanced deep learning techniques. 2024.
- 16. Cassidy B. Analysis of ISIC datasets and benchmarking practices. 2022.
- 17. Brinker TJ, et al. Reader study comparisons of AI vs dermatologists. 2019.
- 18. Rotemberg V, et al. A patient-centered evaluation of mobile apps for skin lesion detection. 2020.
- 19. Tschandl P, et al. Human vs machine: diagnostic performance across datasets. 2019.
- 20. ISIC 2020 Challenge Dataset. (Online resource).
- 21. Codella NCF, et al. Deep learning ensembles for skin lesion analysis. 2019.
- 22. Galdran A, et al. Skin lesion segmentation and evaluation methods. 2020.
- 23. Han SS, et al. Deep learning in dermatology: automatic classification of 12 skin diseases. 2018.
- 24. Haenssle HA, et al. Man vs machine studies in dermoscopy. 2018.
- 25. Popescu D, et al. Mobile dermatoscope prototypes and validation studies. 2019.
- 26. FDA guidance on Software as a Medical Device (SaMD). 2021.
- 27. EMA and MHRA regulatory discussions on AI medical devices. 2022.
- 28. Ribeiro MT, et al. 'Why should I trust you?': Explaining the predictions of any classifier. 2016.
- 29. Selvaraju RR, et al. Grad-CAM: Visual Explanations from Deep Networks via Gradient-based Localization. 2017.
- **30.** Brinker TJ. Calibration and uncertainty in dermatology AI models. 2020.
- 31. Liu Y, et al. Deep learning for skin disease classification across multiple datasets. 2021.
- 32. Wang X, et al. Ensemble deep learning for improved lesion classification. 2020.
- 33. Khan AM, et al. Transfer learning and fine-tuning strategies for dermoscopic images. 2019.
- 34. Codella N, et al. Combining deep learning and classical methods for lesion analysis. 2017.
- 35. Goyal M, et al. Adversarial robustness in medical imaging AI. 2021.
- 36. Daneshjou R, et al. Skin tone and bias considerations in dermatology AI. 2021.
- **37.** Liu Z, et al. Vision transformers applied to dermoscopy. 2022.
- 38. He K, Zhang X, Ren S, Sun J. Deep Residual Learning for Image Recognition (ResNet). 2016.
- 39. Tan M, Le Q. EfficientNet: Rethinking Model Scaling for Convolutional Neural Networks. 2019.
- **40.** Dosovitskiy A, et al. An Image is Worth 16x16 Words: Vision Transformer. 2020.
- 41. Cai Z, et al. Benchmarking AI for skin disease severity assessment. 2025.
- 42. Wongvibulsin S, et al. Clinical validation frameworks for dermatology AI apps. 2023.
- 43. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. 2019.
- 44. Litjens G, et al. A survey on deep learning in medical image analysis. 2017.
- 45. Goyal S, et al. Privacy-preserving ML and federated learning in dermatology. 2021.
- **46.** Nguyen H, et al. Edge deployment optimizations for smartphone dermatology apps. 2022.
- 47. Rotemberg V, et al. Standards for reporting AI in dermatology (TRIPOD-AI, CONSORT-AI suggestions). 2021.
- 48. Harangi B, et al. Data augmentation and oversampling techniques for dermoscopic images. 2019.
- 49. Zahid S, et al. Clinical workflow integration of AI-based triage tools for skin lesions. 2020.
- 50. Smith J, et al. Continuous monitoring and post-market surveillance models for AI medical devices. 2022.

- 51. Future directions and roadmap papers: combining multi-modal data (clinical, dermoscopic, genomic) for improved diagnosis. 2023.
- **52.** "Computer-Aided Diagnosis of Skin Diseases Using Deep Neural Networks", published in Applied Sciences in 2020 (volume 10, article 2488).